Development of AntiRetroviral Therapy In Africa: DART



Joint Clinical Research Centre, Kampala, Uganda
&
Academic Alliance, Mulago Hospital, Uganda

MRC/Uganda Virus Research Institute Programme on AIDS, Entebbe, Uganda
&
TASO, Uganda

University of Zimbabwe, Harare, Zimbabwe

MRC Clinical Trials Unit, UK & Imperial College, UK

Rockefeller Foundation

MRC, UK

DFID, UK

GlaxoSmithKline
Gilead
Boehringer-Ingelheim

Getting DART started

Funding for science and site development secured

Product from Industry negotiated (GSK, Gilead, BMS) for first-line ART for 4-5 years

DFID covered purchase of second-line ART

But to start all needed confidence that complex end-of-trial issues were appropriately covered

How to achieve this?

End of Trial ideas

- Recycling into new trials
  - Large trial with > 3000 patients
- Funds/NGO for special care for participants at the end of trial … Lake Victoria Fund
  - How to administer in multisite & country trial
  - Open-ended funding needed
- Government commitment and pledge
  - Coinciding with GFATM funding
  - Coinciding in Uganda with PEPFAR
  - National commitment to ART scale-up 3 by 5

DART 1 mid-term issues

Pledges will be reviewed and renewed with MoHs as DART moves beyond mid-point.

- Standard first-line vs trial regimens
- Second-line requirements
- "quotas" in centres and respective government ART sites
- Priority – those on ART or those who have not had ARVs?

DART 2 being designed (recycling)

- Renewed issues of drug supply
- End of trial issues – beyond current Public Sector planning

The DART team

- **We thank all the patients and staff from all the centres participating in the DART trial.**
- **Virology Group:** P Kaleebu, D Pillay, V Robertson, D Yirrell, R Enzama, S Tugume, M Chirara, F Lyagoba, C Gale.
- **Joint Clinical Research Centre, Kampala, Uganda:** P Mugyenyi, C Kityo, D Tumukunde, F Ssali, D Atwine, G Mulindwa, G Kabuye, R Byaruhanga, T Bakeimyaga-Grace, H Katabira, E Nimwesiga, G Barungi, S Atwiine, F Ahimbisibwe, S Tugume, T Otim, J Takubwa, M Mulindwa, S Murungi, J Tukamushaba, D Muebesa, H Kyomugisha, J Kagina, L Namale.
- **University of Zimbabwe, Harare, Zimbabwe:** A Latif, J Hakim, V Robertson, A Reid, A Jamu, S Makota, T Mupudzi, G Musoro, N Ngorima, M Pascoe, F Taziwa, L Chakonza, E Chidziva, H Chirairo, S Chitsungo, F Mapinge, A Mawora, C Muvirimi, G Tinago, J Chimanzi, J Machingura, C Maweni, S Mutsai, R Warara, M Matongo, N Mdege, S Mudzingwa, M Jangano, I Machingura, K Moyo, L Vere, E Chigwedere, M Phiri.
- **MRC Programme on AIDS/Uganda Virus Research Institute, Entebbe, Uganda:** H Grosskurth, P Munderi, K Wangati, D Kajungu, B Amuron, D Nsibambi; R Kasirye, E Zalwango, M Nakazibwe, B Kikaire, G Nassuna, R Massa, K Fadhiru, M Namyalo, A Zalwango, L Generous, P Khauka, N Rutikarayo, W Nakahima, A Mugisha, J Nakiyingi, P Hughes.
- **Academic Alliance, Mulago Hospital, Uganda:** E Katabira, J Oyugi, A Ronald, A Kambungu, J Martin, R Nalumenya, R Nairubi, E Bulume, M Teopista, C Twijukye, F Sematala, H Byakwaga.
- **The AIDS Support Organisation (TASO), Uganda:** A Coutinho, B Etukoit.
- **Imperial College:** C Gilks, L Colquhoun, K Boocock, C Puddephatt.
- **MRC Clinical Trials Unit:** J Darbyshire, DM Gibb, A Burke, D Bray, A Babiker, AS Walker, H Wilkes, M Rauchenberger, S Sheehan, C O'Brien.
- **Trial Steering Committee:** I Weller (Chair), A Babiker (Trial Statistician), S Bahendeka, M Bassett, A Chogo Wapakhabulo, J Darbyshire, B Gazzard, C Gilks, H Grosskurth, J Hakim, A Latif, E Loeliger (observer), M Imperiale (observer), O Mugurungi, P Mugyenyi, P Naidoo (observer), M Palmer (observer), J Rooney (observer), J-M Steens (observer).
- **Data and Safety Monitoring Committee:** A McLaren (Chair), C Hill, J Matenga, A Pozniak, D Serwadda
- **GlaxoSmithKline** donated first-line drugs for DART and provided funding for this virology substudy. **Gilead** and **Boehringer-Ingelheim** also donated first-line drugs.
- **Funding:** DART is funded by the **UK Medical Research Council**, the **UK Department for International Development (DFID)**, and the **Rockefeller Foundation**.